One lead asset, ready for the bench. A repeatable engine.
Our lead program targets the single strongest genetic driver of Alzheimer's disease. It was generated and cross-validated entirely in silico — and is ready for experimental confirmation at the bench.
Correcting the shape of risk.
ApoE4 differs from its benign counterpart by a structural quirk that makes the protein misfold and drive neurodegeneration. A small-molecule "structure corrector" can restore a healthier conformation — a mechanism with strong human-genetic and experimental support.
Thea generated a novel series of correctors designed against the only experimentally confirmed small-molecule pocket on ApoE4, then optimized for binding, drug-likeness, and a clean safety profile. Multiple leads cleared multi-parameter ADMET screening; the series is protected by a filed provisional patent.
The most genetically validated target in Alzheimer's — and still undrugged.
Decades of effort, overwhelming human genetics, and a clear mechanism — yet no disease-modifying therapy addresses ApoE4 head-on. That gap is precisely where a computational platform built for hard targets earns its keep.
What we've proven — and what we haven't yet.
We hold a high bar for what counts as validated. Below is an honest accounting of the program's current evidence.
- ✓Designed against an observed pocket.The only experimentally observed small-molecule binding site on ApoE4 (6NCO / 6NCN).
- ✓Strong predicted binding.Lead affinities cross-checked by independent scoring methods (figures under NDA).
- ✓Clean safety profile.Multiple leads cleared multi-parameter ADMET and structural-alert screens.
- ✓Protected IP.Composition-of-matter genus covered by a filed provisional application.
- →Synthesis & biophysical binding.Confirm target engagement at the bench — SPR / ITC, with a co-crystal attempt.
- →Cellular functional assay.Demonstrate structure correction in ApoE4 cell models.
- →In-vitro ADME & stability.Microsomal stability, Caco-2 / MDCK-MDR1 permeability, plasma protein binding.
- →Early pharmacokinetics.Exposure and CNS penetrance in vivo.
- →Lead optimization.Medicinal-chemistry cycles toward an IND-enabling candidate.
Quantitative figures (affinities, screening and lead counts) are computational predictions shared under NDA. Experimental confirmation is the explicit objective of the next phase.
A platform, not a one-off.
Titan proves the engine. The same loop extends to additional genetically validated, structurally anchored targets as the company is resourced.
Programs 02–03 are exploratory and depend on partnership and funding. Titan is the company's lead — cross-validated in silico and IP-protected.
Take Titan into the lab.
We're seeking a strategic partner to fund experimental validation and lead optimization for a patent-pending Alzheimer's program.